{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:44:56Z","timestamp":1780371896284,"version":"3.54.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A hallmark of cancer biology is resistance to apoptosis. BCL-2 is an anti-apoptotic molecule that is being overexpressed in several myeloid diseases, such as acute myeloid leukemia and myelodysplastic syndromes, but also in several lymphoid cancers, such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphomas and multiple myeloma. Venetoclax (VEN) is a BCL-2 small molecule inhibitor. Data about its structure, biochemical characteristics and in vitro efficacy against several blood cancer cell lines were first reported in 2013. Shortly after, the first clinical trials reported that single-agent VEN provides no long-term survival benefits. In contrast, when used in combination, VEN led to significantly improved outcomes and eventually to its first US FDA approvals in 2018. As the modern approach to treating hematological malignancies are the chemotherapy-free regimen, in the current manuscript, we provide a comprehensive view on all available therapies that are considered to be chemotherapy-free, with a special emphasis on acute myeloid leukemia (AML), where phase I-III clinical trials have provided the most data.<\/jats:p>","DOI":"10.1038\/s41420-025-02678-4","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:54:57Z","timestamp":1755086097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and\/or immune therapies"],"prefix":"10.1038","volume":"11","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Tat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin Stefan","family":"Vizitiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Vazar-Tripon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Ilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-9866","authenticated-orcid":false,"given":"Anamaria","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Iluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Jitaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-7944","authenticated-orcid":false,"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3788-1457","authenticated-orcid":false,"given":"Carlo M.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"2678_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov."},{"key":"2678_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440\u20132.","journal-title":"Nature"},{"key":"2678_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.leu.2401302","volume":"13","author":"D Puthier","year":"1999","unstructured":"Puthier D, Pellat-Deceunynck C, Barill\u00e9 S, Robillard N, Rapp MJ, Juge-Morineau N, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia. 1999;13:289\u201394.","journal-title":"Leukemia"},{"key":"2678_CR4","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","volume":"99","author":"JZ Huang","year":"2002","unstructured":"Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285\u201390.","journal-title":"Blood"},{"key":"2678_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151:344\u201355.","journal-title":"Cell"},{"key":"2678_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"2678_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2678_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J. Hematol. 2023;98:502\u201326.","journal-title":"Am J. Hematol."},{"key":"2678_CR9","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3390\/cancers15051617","volume":"15","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, DiNardo CD, Loghavi S. Molecularly targeted therapy in acute myeloid leukemia: current treatment landscape and mechanisms of response and resistance. Cancers. 2023;15:1617.","journal-title":"Cancers"},{"key":"2678_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29.","journal-title":"J Hematol Oncol"},{"key":"2678_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov."},{"key":"2678_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2678_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"2678_CR14","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2023-182045","volume":"142","author":"A Venditti","year":"2023","unstructured":"Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, et al. Outcomes in chemotherapy-ineligible elderly patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine: a pooled analysis. Blood. 2023;142:2886.","journal-title":"Blood"},{"key":"2678_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J. Hematol. 2024;99:615\u201324.","journal-title":"Am J. Hematol"},{"key":"2678_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2021-153288","volume":"138","author":"S Chen","year":"2021","unstructured":"Chen S, Xie J, Yang X, Shen H, Cen J, Yao L, et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: interim analysis of a prospective, multicenter, single-arm, phase 2 trial. Blood. 2021;138:35.","journal-title":"Blood"},{"key":"2678_CR17","doi-asserted-by":"crossref","unstructured":"Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, et al. Decitabine and venetoclax for IDH1\/2 - mutated acute myeloid leukemia. Am J Hematol. 2021. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26122.","DOI":"10.1002\/ajh.26122"},{"key":"2678_CR18","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1182\/blood-2022-167967","volume":"140","author":"IM Johnson","year":"2022","unstructured":"Johnson IM, Ilyas R, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, et al. Molecular predictors of response and survival in patients with relapsed\/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy. Blood. 2022;140:3233\u20134.","journal-title":"Blood"},{"key":"2678_CR19","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica. 2023;108:3170\u20134.","journal-title":"Haematologica"},{"key":"2678_CR20","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5:1552\u201364.","journal-title":"Blood Adv."},{"key":"2678_CR21","doi-asserted-by":"publisher","first-page":"e7378","DOI":"10.1002\/cam4.7378","volume":"13","author":"D Jin","year":"2024","unstructured":"Jin D, He J, Chen H, Wu W, Han X, Le J, et al. Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer Med. 2024;13:e7378.","journal-title":"Cancer Med"},{"key":"2678_CR22","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724\u201336.","journal-title":"Lancet Haematol"},{"key":"2678_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood-2024-199267","volume":"144","author":"JM Watts","year":"2024","unstructured":"Watts JM, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Abbott D, et al. Venetoclax plus azacitidine for newly diagnosed younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy. Blood. 2024;144:969.","journal-title":"Blood"},{"key":"2678_CR24","doi-asserted-by":"publisher","first-page":"1527.1","DOI":"10.1182\/blood-2024-198164","volume":"144","author":"L Kretschmer","year":"2024","unstructured":"Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, et al. Trial in progress: a randomized-controlled phase 2 study evaluating venetoclax plus azacitidine versus intensive chemotherapy in adult patients with newly diagnosed, NPM1 -mutated AML - the SAL\/AMLCG Vincent trial. Blood. 2024;144:1527.1.","journal-title":"Blood"},{"key":"2678_CR25","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/bloodadvances.2024012858","volume":"8","author":"JP Bewersdorf","year":"2024","unstructured":"Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, et al. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1 -mutant AML. Blood Adv. 2024;8:4845\u201355.","journal-title":"Blood Adv."},{"key":"2678_CR26","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/ajh.27366","volume":"99","author":"JP Bewersdorf","year":"2024","unstructured":"Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, et al. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1 - or IDH2 -mutant newly diagnosed acute myeloid leukemia\u2014A multicenter cohort study. Am J. Hematol. 2024;99:1640\u20133.","journal-title":"Am J. Hematol"},{"key":"2678_CR27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2024-197933","volume":"144","author":"CL Wan","year":"2024","unstructured":"Wan CL, Liu YQ, Liu FT, Huang YH, Cao HY, Huang SM, et al. Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: a propensity score matched analysis based on international consensus classification. Blood. 2024;144:1527\u20131527.","journal-title":"Blood"},{"key":"2678_CR28","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2024-202744","volume":"144","author":"LE Aguirre","year":"2024","unstructured":"Aguirre LE, Bewersdorf JP, Liu Y, Shallis RM, Boussi L, Zucenka A, et al. Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics. Blood. 2024;144:4267.","journal-title":"Blood"},{"key":"2678_CR29","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1182\/blood-2024-204467","volume":"144","author":"L Boussi","year":"2024","unstructured":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Zucenka A, et al. Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities. Blood. 2024;144:4281.","journal-title":"Blood"},{"key":"2678_CR30","doi-asserted-by":"crossref","unstructured":"Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, et al. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX -351). Am J Hematol. 2021. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26157.","DOI":"10.1002\/ajh.26157"},{"key":"2678_CR31","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.1182\/blood-2022-169307","volume":"140","author":"RF Little","year":"2022","unstructured":"Little RF, Othus M, Assouline S, Ansher S, Atallah EL, Lindsley RC, et al. Umbrella trial in myeloid malignancies: the myelomatch national clinical trials network precision medicine initiative. Blood. 2022;140:9057\u201360.","journal-title":"Blood"},{"key":"2678_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/blood-2023-181347","volume":"142","author":"J Lu","year":"2023","unstructured":"Lu J, Xue S, Wang Y, Dai HP, He X, Hu X, et al. Comparing the efficacy and safety of venetoclax combined with decitabine versus conventional chemotherapy as induction therapy for young adults with newly diagnosed acute myeloid leukemia - interim analysis of a multicenter, randomized, phase 2b trial. Blood. 2023;142:970.","journal-title":"Blood"},{"key":"2678_CR33","doi-asserted-by":"crossref","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol. 2024. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27180.","DOI":"10.1002\/ajh.27180"},{"key":"2678_CR34","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1182\/blood-2023-185079","volume":"142","author":"S Boisclair","year":"2023","unstructured":"Boisclair S, Naing PT, Zhou E, Thakur R, Jou E, Goldberg B, et al. Outcomes and hospital resource utilization associated with decreased ven exposure in acute myeloid leukemia patients: a real-world retrospective review. Blood. 2023;142:4268.","journal-title":"Blood"},{"key":"2678_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107545","volume":"143","author":"S Boisclair","year":"2024","unstructured":"Boisclair S, Zhou E, Naing P, Thakur R, Jou E, Goldberg B, et al. Less is more: an analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML. Leuk Res. 2024;143:107545.","journal-title":"Leuk Res"},{"key":"2678_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2293512","volume":"29","author":"J Cui","year":"2024","unstructured":"Cui J, Chen X, Li C, Yan Q, Yuan G. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Hematology. 2024;29:2293512.","journal-title":"Hematology"},{"key":"2678_CR37","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1182\/blood-2024-209246","volume":"144","author":"AA Ginosyan","year":"2024","unstructured":"Ginosyan AA, Ashouri K, Humayun L, Ford L, Baya M, Hong HJ, et al. Optimizing venetoclax duration in combination with hypomethylating agents for newly diagnosed AML: impact on treatment response and survival outcomes. Blood. 2024;144:2892.","journal-title":"Blood"},{"key":"2678_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, et al. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J. 2025;15:68.","journal-title":"Blood Cancer J."},{"key":"2678_CR39","doi-asserted-by":"crossref","unstructured":"Gangat N, Tefferi A. Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J. 2025;15:56.","DOI":"10.1038\/s41408-025-01270-4"},{"key":"2678_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01189-2","volume":"14","author":"X Suo","year":"2024","unstructured":"Suo X, Ma X, Zheng F, Wang D, Bai G, Zhao L, et al. Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia. Blood Cancer J. 2024;14:204.","journal-title":"Blood Cancer J."},{"key":"2678_CR41","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1016\/S2352-3026(24)00034-6","volume":"11","author":"A Bazinet","year":"2024","unstructured":"Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, et al. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;11:e287\u201398.","journal-title":"Lancet Haematol."},{"key":"2678_CR42","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2024025834","volume":"144","author":"M Goldfinger","year":"2024","unstructured":"Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, et al. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024;144:2360\u20133.","journal-title":"Blood"},{"key":"2678_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40:855\u201365.","journal-title":"J Clin Oncol"},{"key":"2678_CR44","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3324\/haematol.2023.282681","volume":"108","author":"JA Gutman","year":"2023","unstructured":"Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, et al. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023;108:2616\u201325.","journal-title":"Haematologica"},{"key":"2678_CR45","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1182\/blood-2024-208817","volume":"144","author":"M Carre","year":"2024","unstructured":"Carre M, Meunier M, Gross Z, Aspas Requena G, Tauveron-Jalenques U, Tavernier E, et al. Azacytidine and venetoclax as a salvage therapy in measurable residual disease (MRD) relapse post intensive chemotherapy or allogenic stem cell transplantation in acute myeloid leukemia patients: a multicentric study from French Auraml Group. Blood. 2024;144:4335\u20134335.","journal-title":"Blood"},{"key":"2678_CR46","doi-asserted-by":"crossref","unstructured":"Jamy O, Lin K, Worth S, Bachiashvili K, Rangaraju S, Vachhani P, et al. Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2022. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18229.","DOI":"10.1111\/bjh.18229"},{"key":"2678_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3274","volume":"42","author":"S Manda","year":"2024","unstructured":"Manda S, Anz BM, Benton C, Broun ER, Yimer HA, Renshaw JS, et al. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematol Oncol. 2024;42:e3274.","journal-title":"Hematol Oncol."},{"key":"2678_CR48","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1182\/blood-2023-182966","volume":"142","author":"ML Amaya","year":"2023","unstructured":"Amaya ML, McMahon CM, Schwartz M, Gutman JA, Sohalski C, Tobin J, et al. Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for relapsed and refractory acute myeloid leukemia. Blood. 2023;142:2914.","journal-title":"Blood"},{"key":"2678_CR49","doi-asserted-by":"publisher","first-page":"e19011","DOI":"10.1200\/JCO.2023.41.16_suppl.e19011","volume":"41","author":"S Fleming","year":"2023","unstructured":"Fleming S, Roboz GJ, Fathi AT, Zhang TY, Wei A, Carraway HE, et al. Phase 1b OMNIVERSE trial: safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia. J Clin. Oncol. 2023;41:e19011.","journal-title":"J Clin. Oncol."},{"key":"2678_CR50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1182\/blood-2021-146264","volume":"138","author":"GN Mannis","year":"2021","unstructured":"Mannis GN, Griffiths EA, Savona MR, Odenike O, Roboz GJ, O\u2019Connell CL, et al. A phase 1 study evaluating ASTX727 (decitabine and cedazuridine) and venetoclax combination therapy in newly diagnosed AML patients unfit for intensive induction chemotherapy. Blood. 2021;138:1245.","journal-title":"Blood"},{"key":"2678_CR51","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S2352-3026(24)00033-4","volume":"11","author":"A Bazinet","year":"2024","unstructured":"Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, et al. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024;11:e276\u201386.","journal-title":"Lancet Haematol."},{"key":"2678_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2023-172658","volume":"142","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Garcia-Manero G, Short NJ, Alvarado Valero Y, Abuasab T, Islam MR, et al. A phase 2 study of the fully oral combination of ASTX727 (decitabine\/cedazuridine) plus venetoclax for older and\/or unfit patients with acute myeloid leukemia. Blood. 2023;142:833.","journal-title":"Blood"},{"key":"2678_CR53","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2023-173092","volume":"142","author":"K Geissler","year":"2023","unstructured":"Geissler K, Koristek Z, Bernal Del Castillo T, Novak J, Rodriguez Macias G, Metzelder S, et al. Oral decitabine\/cedazuridine vs intravenous decitabine for acute myeloid leukemia: final results of a randomized, crossover, registration-enabling, pharmacokinetics study. Blood. 2023;142:1538.","journal-title":"Blood"},{"key":"2678_CR54","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1182\/blood-2023-182901","volume":"142","author":"A Maiti","year":"2023","unstructured":"Maiti A, DiNardo CD, Ohanian M, Daver N, Borthakur G, Chien KS, et al. Phase II trial of 10-day ASTX727 (decitabine\/cedazuridine) with venetoclax for relapsed or refractory acute myeloid leukemia. Blood. 2023;142:4289.","journal-title":"Blood"},{"key":"2678_CR55","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-2023-172883","volume":"142","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kantarjian HM, Ravandi F, Short NJ, Daver N, Ohanian M, et al. Decitabine\/cedazuridine (ASTX727) combined with a molecularly-targeted agent (venetoclax, gilteritinib, ivosidenib, or enasidenib) as personalized maintenance therapy in acute myeloid leukemia: first results from a phase 1b study. Blood. 2023;142:2909.","journal-title":"Blood"},{"key":"2678_CR56","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, et al. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024;11:e830\u20138.","journal-title":"Lancet Haematol."},{"key":"2678_CR57","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2024-210315","volume":"144","author":"C Sartor","year":"2024","unstructured":"Sartor C, Candoni A, Piciocchi A, Marsili G, Fazi P, Papayannidis C, et al. Venetoclax and azacitidine for relapse prevention in NPM1 -mutated acute myeloid leukemia in molecular failure: results from the ongoing Gimema AML2521 phase 2 trial. Blood. 2024;144:2893.","journal-title":"Blood"},{"key":"2678_CR58","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood-2024-203496","volume":"144","author":"E Tavernier","year":"2024","unstructured":"Tavernier E, Cornillon J, Gross Z, Aspas Requena G, Tauveron-Jalenques U, Carr\u00e9 M, et al. Azacitidine and venetoclax as a salvage therapy for relapse after allogeneic transplantation for acute myeloid leukemia: a multicentric study from French Auraml Group. Blood. 2024;144:1518.","journal-title":"Blood"},{"key":"2678_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.841276","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Wang J, Ge SS, Qiu QC, Du JH, Shan SS, et al. Combination of venetoclax and midostaurin efficiently suppressed relapsed t(8;21)acute myeloid leukemia with mutant KIT after failure of venetoclax plus azacitidine treatment. Front Oncol. 2022;12:841276.","journal-title":"Front Oncol"},{"key":"2678_CR60","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357.","journal-title":"Blood"},{"key":"2678_CR61","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3 -mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048\u201359.","journal-title":"J Clin Oncol"},{"key":"2678_CR62","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3 -mutated AML. J Clin Oncol. 2024;42:1499\u2013508.","journal-title":"J Clin Oncol."},{"key":"2678_CR63","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood-2024-210891","volume":"144","author":"NJ Short","year":"2024","unstructured":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Jabbour JE, DiNardo CD, et al. Long-term survival outcomes and cytogenetic\/molecular patterns of relapse in adults with FLT3 -mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor. Blood. 2024;144:220.","journal-title":"Blood"},{"key":"2678_CR64","doi-asserted-by":"crossref","unstructured":"Liu Q (Selina), Welkie RL, Huang Y, Swords RT, Lin TL, Koenig KL, et al. Beat AML S8 group 2: gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age \u226560 with high and low variant allele frequency (VAF). Blood. 2023;142:5933.","DOI":"10.1182\/blood-2023-179609"},{"key":"2678_CR65","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood-2023-187429","volume":"142","author":"R Briski","year":"2023","unstructured":"Briski R, Short NJ, Daver N, Kadia TM, DiNardo CD, Yilmaz M, et al. A phase I\/II study of combination of ASTX727, gilteritinib and venetoclax in patients with relapsed\/refractory FLT3 mutated acute myeloid leukemia (AML). Blood. 2023;142:2910.","journal-title":"Blood"},{"key":"2678_CR66","doi-asserted-by":"publisher","first-page":"2907.1","DOI":"10.1182\/blood-2024-199701","volume":"144","author":"JK Altman","year":"2024","unstructured":"Altman JK, Sun Z, Perl AE, Little R, Gore SD, Michaelis LC, et al. A randomized phase II study of venetoclax and HMA-based therapies for the treatment of older and unfit adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML): a myelomatch treatment trial: ECOG-ACRIN MM20A-EA02. Blood. 2024;144:2907.1.","journal-title":"Blood"},{"key":"2678_CR67","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.HS9.0000844936.55710.7c","volume":"6","author":"JM Bergua-Burgues","year":"2022","unstructured":"Bergua-Burgues JM, Rodr\u00edguez-Veiga R, Cano I, Vall-llovera F, Garc\u00eda-Gui\u00f1on A, G\u00f3mez-Estruch J, et al. P512: preliminary results of Ven-a-Qui study: a phase 1-2 trial to assess the safety and efficacy of the ombination of azacitidine or low-dose cytarabine with venetoclax and quizartinib in newly diagnosed. HemaSphere. 2022;6:411\u20132.","journal-title":"HemaSphere"},{"key":"2678_CR68","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1200\/JCO.2022.40.16_suppl.7036","volume":"40","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Muftuoglu M, Kantarjian HM, Dinardo CD, Kadia TM, Konopleva M, et al. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): a phase I\/II clinical trial. J Clin Oncol. 2022;40:7036.","journal-title":"J Clin Oncol"},{"key":"2678_CR69","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood-2024-204296","volume":"144","author":"M Yilmaz","year":"2024","unstructured":"Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, et al. Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood. 2024;144:4263.","journal-title":"Blood"},{"key":"2678_CR70","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1182\/blood-2024-200397","volume":"144","author":"N Daver","year":"2024","unstructured":"Daver N, Lee KH, Choi Y, Montesinos P, Jonas BA, Arellano ML, et al. Phase 1 safety and efficacy of tuspetinib plus venetoclax combination therapy in study participants with relapsed or refractory acute myeloid leukemia (AML) support exploration of triplet combination therapy of tuspetinib plus venetoclax and azacitidine for newly diagnosed AML. Blood. 2024;144:4255.","journal-title":"Blood"},{"key":"2678_CR71","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1182\/blood-2023-182296","volume":"142","author":"N Daver","year":"2023","unstructured":"Daver N, Lee KH, Choi Y, Jonas BA, Arellano M, Koller PB, et al. Tuspetinib myeloid kinase inhibitor safety and efficacy as monotherapy and combined with venetoclax in phase 1\/2 trial of patients with relapsed or refractory (R\/R) acute myeloid leukemia (AML). Blood. 2023;142:162.","journal-title":"Blood"},{"key":"2678_CR72","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2023-187060","volume":"142","author":"MP Ozga","year":"2023","unstructured":"Ozga MP, Dvorak-Kornaus KM, Zhao Q, Buss J, Laganson A, Hamp E, et al. I-DATA study: randomized, sequential, open-label study to evaluate the efficacy of IDH targeted\/non- targeted versus non-targeted\/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated adult AML patients not candidates for intensive induction therapy. Blood. 2023;142:1534.","journal-title":"Blood"},{"key":"2678_CR73","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393.","journal-title":"Blood Cancer Discov."},{"key":"2678_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2024-200393","volume":"144","author":"J Marvin-Peek","year":"2024","unstructured":"Marvin-Peek J, Garcia JS, Borthakur G, Garcia-Manero G, Short NJ, Kadia TM, et al. A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated hematologic malignancies: a 2024 update. Blood. 2024;144:219.","journal-title":"Blood"},{"key":"2678_CR75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2023-188341","volume":"142","author":"G Richard-Carpentier","year":"2023","unstructured":"Richard-Carpentier G, Gupta G, Cameron C, Cathelin S, Bankar A, Davidson MB, et al. Final results of the phase Ib\/II study evaluating enasidenib in combination with venetoclax in patients with IDH2-mutated relapsed\/refractory myeloid malignancies. Blood. 2023;142:159.","journal-title":"Blood"},{"key":"2678_CR76","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1182\/blood-2023-182944","volume":"142","author":"H Atluri","year":"2023","unstructured":"Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, et al. Phase Ib\/2 study of oral decitabine\/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 update. Blood. 2023;142:968.","journal-title":"Blood"},{"key":"2678_CR77","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2024-200387","volume":"144","author":"J Marvin-Peek","year":"2024","unstructured":"Marvin-Peek J, Atluri H, Short NJ, Maiti A, Takahashi K, Loghavi S, et al. Clinical outcomes using frontline \u201cTriplet\u201d regimens for newly diagnosed IDH-mutated acute myeloid leukemia (AML): a pooled analysis of two phase Ib\/2 clinical trials. Blood. 2024;144:2883.","journal-title":"Blood"},{"key":"2678_CR78","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1182\/blood-2024-199170","volume":"144","author":"AT Fathi","year":"2024","unstructured":"Fathi AT, Issa GC, Wang ES, Erba H, Altman JK, Balasubramanian SK, et al. Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1 -m or KMT2A -r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144:2880.","journal-title":"Blood"},{"key":"2678_CR79","doi-asserted-by":"publisher","first-page":"1504.4","DOI":"10.1182\/blood-2024-208146","volume":"144","author":"D McCall","year":"2024","unstructured":"McCall D, Cuglievan B, Gibson A, Garcia MB, Roth ME, Nunez C. A Phase I study investigating the combination of the ziftomenib, venetoclax and azacitidine (ZiVA) in pediatric relapsed and refractory acute leukemias. Blood. 2024;144:1504.4.","journal-title":"Blood"},{"key":"2678_CR80","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, et al. Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML. Blood. 2024;144:216.","journal-title":"Blood"},{"key":"2678_CR81","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1182\/blood-2023-186204","volume":"142","author":"MC Kwon","year":"2023","unstructured":"Kwon MC, Verhulst T, Goffin D, Marien A, Verbist B, Guttke C, et al. Preclinical efficacy of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in AML. Blood. 2023;142:4167.","journal-title":"Blood"},{"key":"2678_CR82","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, et al. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1\/FLT3-ITD\/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023. https:\/\/haematologica.org\/article\/view\/haematol.2022.281927.","DOI":"10.3324\/haematol.2022.281927"},{"key":"2678_CR83","doi-asserted-by":"publisher","first-page":"4265.2","DOI":"10.1182\/blood-2024-201582","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Ambinder AJ, Xiao W, Manalis S, Shalek AK, Gondek LP, et al. A multi-site break through cancer trial: phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (Trial In progress). Blood. 2024;144:4265.2.","journal-title":"Blood"},{"key":"2678_CR84","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","volume":"106","author":"K Kojima","year":"2005","unstructured":"Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150\u20139.","journal-title":"Blood"},{"key":"2678_CR85","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141:1265\u201376.","journal-title":"Blood"},{"key":"2678_CR86","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/blood-2021-144650","volume":"138","author":"AH Wei","year":"2021","unstructured":"Wei AH, Breccia M, Ooi M, Cedena Romero MT, Ciceri F, Erba HP, et al. Preliminary results from a phase Ib study exploring MDM2 inhibitor siremadlin (HDM201) in combination with B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). Blood. 2021;138:1283.","journal-title":"Blood"},{"key":"2678_CR87","doi-asserted-by":"publisher","first-page":"11625","DOI":"10.1182\/blood-2022-167326","volume":"140","author":"N Daver","year":"2022","unstructured":"Daver N, Wei AH, Stein E, DeAngelo DJ, Pathak D, Xu Y, et al. Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: a phase Ib\/II trial. Blood. 2022;140:11625\u20137.","journal-title":"Blood"},{"key":"2678_CR88","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","volume":"10","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023;10:e272\u201383.","journal-title":"Lancet Haematol."},{"key":"2678_CR89","doi-asserted-by":"publisher","first-page":"107206","DOI":"10.18632\/oncotarget.22284","volume":"8","author":"J Bogenberger","year":"2017","unstructured":"Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8:107206\u201322.","journal-title":"Oncotarget"},{"key":"2678_CR90","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/hon.3159","volume":"41","author":"BA Jonas","year":"2023","unstructured":"Jonas BA, Hou J, Roboz GJ, Alvares CL, Jeyakumar D, Edwards JR, et al. A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia. Hematol Oncol. 2023;41:743\u201352.","journal-title":"Hematol Oncol."},{"key":"2678_CR91","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2024-198718","volume":"144","author":"Y Alvarado-Valero","year":"2024","unstructured":"Alvarado-Valero Y, Cook RJ, Dinner SN, Keng M, Begna K, Abedin S, et al. A phase 1 study of the oral CDK9 inhibitor voruciclib in combination with venetoclax in relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood. 2024;144:2878.","journal-title":"Blood"},{"key":"2678_CR92","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2024-199412","volume":"144","author":"M Wu","year":"2024","unstructured":"Wu M, Zhang Y, Wu W, Ge Z, Liu L, Ji C, et al. High remission rates in relapsed\/refractory acute myeloid leukemia with QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen): preliminary results of a phase 2a study. Blood. 2024;144:2882.","journal-title":"Blood"},{"key":"2678_CR93","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, et al. Inhibition of XPO 1 enhances cell death induced by ABT -199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med. 2018;22:6099\u2013111.","journal-title":"J Cell Mol Med"},{"key":"2678_CR94","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/blood-2023-184581","volume":"142","author":"L Yang","year":"2023","unstructured":"Yang L, Chen F, Liang H, Bai Y, Wu W, Yan X, et al. Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study. Blood. 2023;142:55.","journal-title":"Blood"},{"key":"2678_CR95","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3324\/haematol.2018.205534","volume":"105","author":"L Han","year":"2020","unstructured":"Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697\u2013707.","journal-title":"Haematologica"},{"key":"2678_CR96","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000525566","volume":"145","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, et al. A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations. Acta Haematol. 2022;145:529\u201336.","journal-title":"Acta Haematol."},{"key":"2678_CR97","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.clml.2024.01.007","volume":"24","author":"MY Konopleva","year":"2024","unstructured":"Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, et al. Venetoclax and cobimetinib in relapsed\/refractory AML: a phase 1b trial. Clin Lymphoma Myeloma Leuk. 2024;24:364\u201374.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2678_CR98","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cncr.33590","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Cancer. 2021;127:2943\u201353.","journal-title":"Cancer"},{"key":"2678_CR99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-023-01476-8","volume":"16","author":"NJ Short","year":"2023","unstructured":"Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, et al. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023;16:73.","journal-title":"J Hematol Oncol"},{"key":"2678_CR100","doi-asserted-by":"crossref","unstructured":"Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, et al. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Haematologica. 2024. https:\/\/haematologica.org\/article\/view\/haematol.2024.285014.","DOI":"10.3324\/haematol.2024.285014"},{"key":"2678_CR101","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","volume":"40","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Winer ES, DeAngelo DJ, Tarantolo SR, Sallman DA, Dugan J, et al. Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome. J Clin Oncol. 2022;40:7016.","journal-title":"J Clin Oncol"},{"key":"2678_CR102","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1182\/blood-2024-212328","volume":"144","author":"BA Jonas","year":"2024","unstructured":"Jonas BA, Karanjawala ZE, Molnar L, Dang-Chu AL, Abedi M, Esteghamat NS, et al. Updated results of a phase I study of uproleselan combined with azacitidine and venetoclax for the treatment of older or unfit patients with treatment na\u00efve acute myeloid leukemia. Blood. 2024;144:1503.","journal-title":"Blood"},{"key":"2678_CR103","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2023-191166","volume":"142","author":"UM Borate","year":"2023","unstructured":"Borate UM, Madanat YF, Tognon C, Mishra S, Kaempf A, Patel PA, et al. Results of a phase 1 trial testing the novel combination therapy of venetoclax and ruxolitinib in relapsed\/refractory acute myeloid leukemia patients. Blood. 2023;142:1515.","journal-title":"Blood"},{"key":"2678_CR104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-140729","volume":"136","author":"L Wilde","year":"2020","unstructured":"Wilde L, Martinez-Outschoorn U, Palmisiano N, Keiffer G, Kasner M. Results of the phase 1b dose escalation study of OPB-111077, decitabine, and venetoclax for the treatment of newly diagnosed or relapsed\/refractory AML. Blood. 2020;136:10.","journal-title":"Blood"},{"key":"2678_CR105","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1182\/blood-2024-210370","volume":"144","author":"JM Stempel","year":"2024","unstructured":"Stempel JM, Uy GL, Dinner SN, Gojo I, Reed D, Roy R, et al. Efficacy and safety of pembrolizumab added to azacitidine plus venetoclax for patients with acute myeloid leukemia: results from an investigator-initiated, multi-center, CTEP-sponsored randomized, phase II trial (BLAST AML-2). Blood. 2024;144:736.","journal-title":"Blood"},{"key":"2678_CR106","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","volume":"63","author":"NJ Short","year":"2022","unstructured":"Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, et al. A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma. 2022;63:2161\u201370.","journal-title":"Leuk Lymphoma"},{"key":"2678_CR107","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2024-203706","volume":"144","author":"S Arora","year":"2024","unstructured":"Arora S, Senapati J, Loghavi S, Reville PK, Wang B, Kadia TM, et al. Phase 1b\/2 study of magrolimab (Magro), azacitidine (AZA) and venetoclax (VEN) in patients (pts) with newly diagnosed (ND) older\/unfit or high risk acute myeloid leukemia (AML) and relapsed refractory (R\/R) AML: final clinical data and genomic markers of resistance\/relapse. Blood. 2024;144:735.","journal-title":"Blood"},{"key":"2678_CR108","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","volume":"22","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Westermann J, Kovacsovics T, Assouline S, Schuh AC, Kim HJ, et al. AML-484 first results of a phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML). Clin Lymphoma Myeloma Leuk. 2022;22:S255.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2678_CR109","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2024-209848","volume":"144","author":"AT Fathi","year":"2024","unstructured":"Fathi AT, Filipovic A, Maher K, Schaar DG, Niroula R, Maly JJ, et al. A phase I dose escalation and expansion trial of Lyt-200 (a first-in-class anti-galectin-9 antibody) alone and in combination with venetoclax\/HMA in relapsed\/refractory AML\/MDS. Blood. 2024;144:1499.","journal-title":"Blood"},{"key":"2678_CR110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11:68\u201379.","journal-title":"Cancer Discov."},{"key":"2678_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, et al. Toxicity in the era of immune checkpoint inhibitor therapy. Front Immunol. 2024;15:1447021.","journal-title":"Front Immunol."},{"key":"2678_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1255825","volume":"15","author":"C Zhang","year":"2024","unstructured":"Zhang C, Wei F, Ma W, Zhang J. Immune-related cardiovascular toxicities of PD-1\/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis. Front Immunol. 2024;15:1255825.","journal-title":"Front Immunol."},{"key":"2678_CR113","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139:3594\u2013604.","journal-title":"Blood"},{"key":"2678_CR114","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(23)00207-7","volume":"10","author":"T Pabst","year":"2023","unstructured":"Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto LM, Guttke C, et al. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. Lancet Haematol. 2023;10:e902\u201312.","journal-title":"Lancet Haematol"},{"key":"2678_CR115","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2021-150371","volume":"138","author":"GJ Roboz","year":"2021","unstructured":"Roboz GJ, Pabst T, Aribi A, Brandwein JM, D\u00f6hner H, Fiedler W, et al. Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; an open-label, multicenter, phase 1b study. Blood. 2021;138:369.","journal-title":"Blood"},{"key":"2678_CR116","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/cam4.3665","volume":"10","author":"R Garg","year":"2021","unstructured":"Garg R, Allen KJH, Dawicki W, Geoghegan EM, Ludwig DL, Dadachova E. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Med. 2021;10:1128\u201340.","journal-title":"Cancer Med"},{"key":"2678_CR117","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood-2023-178802","volume":"142","author":"GJ Sloboz","year":"2023","unstructured":"Sloboz GJ, Finn LE, Orozco JJ, Hegazi M, Desai A, Chen M, et al. Updated results from phase 1 study of targeted radiotherapy with lintuzumab-Ac225 in combination with venetoclax in relapsed\/refractory AML. Blood. 2023;142:1539.","journal-title":"Blood"},{"key":"2678_CR118","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","volume":"8","author":"AA Lane","year":"2024","unstructured":"Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024;8:591\u2013602.","journal-title":"Blood Adv."},{"key":"2678_CR119","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2023-173413","volume":"142","author":"N Daver","year":"2023","unstructured":"Daver N, Montesinos P, Altman JK, Wang ES, Martinelli G, Roboz GJ, et al. Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. Blood. 2023;142:2906.","journal-title":"Blood"},{"key":"2678_CR120","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1182\/blood-2023-182885","volume":"142","author":"A Maiti","year":"2023","unstructured":"Maiti A, Muftuoglu M, Ignatz-Hoover JJ, DiNardo CD, Ravandi F, Andreeff M, et al. Azacitidine, venetoclax and allogeneic NK cells in newly diagnosed acute myeloid leukemia (ADVENT-AML): an investigator-initiated multicenter phase Ib trial. Blood. 2023;142:4863.","journal-title":"Blood"},{"key":"2678_CR121","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood-2022-169509","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, et al. ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140:1441\u20134.","journal-title":"Blood"},{"key":"2678_CR122","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","volume":"8","author":"FW Hoff","year":"2024","unstructured":"Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, et al. Beat-AML 2024 ELN\u2013refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024;8:5297\u2013305.","journal-title":"Blood Adv."},{"key":"2678_CR123","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144:2211\u201322.","journal-title":"Blood"},{"key":"2678_CR124","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8:927\u201335.","journal-title":"Blood Adv."},{"key":"2678_CR125","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax + hypomethylating agent. Am J Hematol. 2025;100:260\u201371.","journal-title":"Am J Hematol."},{"key":"2678_CR126","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/cancers14143456","volume":"14","author":"MS Griffioen","year":"2022","unstructured":"Griffioen MS, De Leeuw DC, Janssen JJWM, Smit L. Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies. Cancers. 2022;14:3456.","journal-title":"Cancers"},{"key":"2678_CR127","doi-asserted-by":"crossref","unstructured":"Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, et al. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica. 2024. https:\/\/haematologica.org\/article\/view\/haematol.2024.285225.","DOI":"10.3324\/haematol.2024.285225"},{"key":"2678_CR128","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1182\/blood-2024-208159","volume":"144","author":"DY Diaz Rohena","year":"2024","unstructured":"Diaz Rohena DY, Mitchell AD, Wang J, Chamberlain S, Liu C, Sanchez JR, et al. Protein degrader WH25244 eliminates venetoclax resistance factors: mutant or hyperphosphorylated BCL2, and BCL-XL. Blood. 2024;144:2786.","journal-title":"Blood"},{"key":"2678_CR129","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2024-202430","volume":"144","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Tan Y, Zhao X, Suo X, Bai G, Bai Y, et al. Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in the treatment of adult patients with de novo acute myeloid leukemia. Blood. 2024;144:4279.","journal-title":"Blood"},{"key":"2678_CR130","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541\u20136.","journal-title":"Ann Hematol."},{"key":"2678_CR131","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2024-200013","volume":"144","author":"M Kanaya","year":"2024","unstructured":"Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, et al. Evaluation of venetoclax duration in venetoclax-azacitidine regimen for untreated acute myeloid leukemia: real world experience from Hokkaido leukemia net. Blood. 2024;144:6063.","journal-title":"Blood"},{"key":"2678_CR132","first-page":"290","volume":"11","author":"S Mirgh","year":"2021","unstructured":"Mirgh S, Sharma A, Shaikh MRMA, Kadian K, Agrawal N, Khushoo V, et al. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11:290\u2013302.","journal-title":"Am J Blood Res"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02678-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:34:53Z","timestamp":1757388893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02678-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02678-4","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}